AIP
ALXN

Ameritas Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Ameritas Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,757
Closed -$1.43M – 3107
2021
Q2 		$1.43M Buy
7,757
+107
+1% +$18.4K 0.05% 459
2021
Q1 		$1.17M Sell
7,650
-80
-1% -$12.4K 0.04% 536
2020
Q4 		$1.21M Buy
7,730
+80
+1% +$10.3K 0.06% 455
2020
Q3 		$875K Sell
7,650
-370
-5% -$39.9K 0.04% 521
2020
Q2 		$900K Hold
8,020
– – 0.04% 495
2020
Q1 		$720K Sell
8,020
-198
-2% -$19.4K 0.04% 496
2019
Q4 		$889K Buy
8,218
+205
+3% +$21.9K 0.04% 569
2019
Q3 		$785K Sell
8,013
-125
-2% -$14.1K 0.04% 594
2019
Q2 		$1.07M Buy
8,138
+85
+1% +$11K 0.05% 484
2019
Q1 		$1.09M Buy
8,053
+30
+0.4% +$3.73K 0.05% 471
2018
Q4 		$781K Buy
8,023
+96
+1% +$11.3K 0.04% 556
2018
Q3 		$1.1M Sell
7,927
-274
-3% -$34.4K 0.05% 494
2018
Q2 		$1.02M Sell
8,201
-400
-5% -$46.7K 0.05% 529
2018
Q1 		$959K Sell
8,601
-352
-4% -$42.1K 0.05% 534
2017
Q4 		$1.07M Sell
8,953
-241
-3% -$29.4K 0.05% 519
2017
Q3 		$1.31M Hold
9,194
– – 0.06% 408
2017
Q2 		$1.12M Hold
9,194
– – 0.05% 483
2017
Q1 		$1.11M Sell
9,194
-194
-2% -$25K 0.06% 467
2016
Q4 		$1.15M Hold
9,388
– – 0.06% 449
2016
Q3 		$1.15M Buy
9,388
+1,005
+12% +$129K 0.06% 417
2016
Q2 		$979K Buy
8,383
+358
+4% +$50.8K 0.06% 307
2016
Q1 		$1.12M Sell
8,025
-1,638
-17% -$241K 0.07% 266
2015
Q4 		$1.84M Sell
9,663
-9,572
-50% -$1.67M 0.12% 177
2015
Q3 		$3.01M Buy
19,235
+415
+2% +$75.7K 0.22% 89
2015
Q2 		$3.4M Buy
18,820
+1,596
+9% +$275K 0.22% 88
2015
Q1 		$2.98M Buy
17,224
+1,837
+12% +$333K 0.2% 109
2014
Q4 		$2.85M Buy
15,387
+22
+0.1% +$4.08K 0.2% 113
2014
Q3 		$2.55M Sell
15,365
-445
-3% -$73.1K 0.18% 124
2014
Q2 		$2.47M Sell
15,810
-298
-2% -$47.1K 0.18% 128
2014
Q1 		$2.45M Sell
16,108
-243
-1% -$38.6K 0.19% 124
2013
Q4 		$2.17M Buy
16,351
+3,799
+30% +$456K 0.17% 144
2013
Q3 		$1.46M Buy
12,552
+4,152
+49% +$456K 0.14% 199
2013
Q2 		$775K Buy
+8,400
New +$809K 0.21% 184

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Ameritas Investment Partners's ALXN Position: Q3 2021 in Review

Ameritas Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,757 shares — an estimated $1.43M sold.

Ameritas Investment Partners first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $3.4M in Q2 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Ameritas Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 7,757 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.43M.
  • Ameritas Investment Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Ameritas Investment Partners's Alexion Pharmaceuticals position peaked at $3.4M in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Ameritas Investment Partners's 13F filing for Q3 2021, filed 15 Nov 2021.